Comparative Pharmacology
Head-to-head clinical analysis: GANCICLOVIR SODIUM versus XOFLUZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANCICLOVIR SODIUM versus XOFLUZA.
GANCICLOVIR SODIUM vs XOFLUZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ganciclovir is a synthetic guanine derivative that inhibits viral DNA synthesis. It is phosphorylated to ganciclovir triphosphate by viral thymidine kinase (CMV UL97 gene product) and cellular kinases. Ganciclovir triphosphate competitively inhibits viral DNA polymerase (CMV UL54 gene product) and incorporates into viral DNA, causing chain termination.
Baloxavir marboxil is a prodrug that is converted to baloxavir acid, which inhibits the cap-dependent endonuclease activity of the influenza virus polymerase acidic protein, thereby preventing viral mRNA transcription and replication.
5 mg/kg IV every 12 hours for 14-21 days for induction; 5 mg/kg IV once daily or 6 mg/kg IV once daily 5 days per week for maintenance. Oral ganciclovir not available as sodium salt.
40 mg orally once as a single dose; for patients weighing ≥80 kg, 80 mg orally once as a single dose.
None Documented
None Documented
Terminal half-life: 2.5-3.6 hours in normal renal function; prolonged in renal impairment (up to 30 hours in severe cases). Dosage adjustment required for CrCl <80 mL/min.
The terminal elimination half-life of baloxavir marboxil is approximately 79.1 hours (range 53–107 hours), supporting single-dose therapy for influenza.
Renal: >90% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <1%.
Baloxavir marboxil is primarily excreted via feces (80.1%) and urine (14.7%) after oral administration, with <1% as unchanged drug in urine.
Category D/X
Category C
Antiviral
Antiviral